Yau J C, Yap Y Y, Buzdar A U, Hortobagyi G N, Bodey G P, Blumenschein G R
Cancer. 1985 Jan 15;55(2):337-40. doi: 10.1002/1097-0142(19850115)55:2<337::aid-cncr2820550205>3.0.co;2-u.
The therapeutic efficacy of vincristine, vinblastine, and vindesine were evaluated in a prospective randomized trial in patients with metastatic breast carcinoma. All patients were refractory to doxorubicin-containing chemotherapy. Vincristine was administered at 0.4 mg/m2/1/day by continuous infusion (CI), vinblastine at 1.7 mg/M2/1/day by CI, and vindesine at 1.2 mg/M2/1/day by CI or intermittent bolus (IB) over 5 days. The courses were administered at 2-week intervals for vincristine and 3-week intervals for vinblastine and vindesine. Ninety-nine patients were evaluable for response. The 15 patients treated with vincristine had no objective response. Of 23 patients treated with vinblastine, there were 2 complete responses (9%) and 5 partial responses (22%). Of 31 patients treated with CI vindesine, there were 6 partial responses (19%). Of 30 patients treated with IB vindesine, there were 5 partial responses (17%). The median duration of disease control was 13 weeks (range, 8-140+) for vinblastine, 18 weeks (range, 8-34) for CI vindesine, and 20 weeks (range, 12-47) for IB vindesine. These data illustrate that vinblastine (CI) and vindesine (CI or IB) have significant antitumor activity in patients with refractory metastatic breast carcinoma and that vincristine has not antitumor activity in similar patients.
在一项针对转移性乳腺癌患者的前瞻性随机试验中，评估了长春新碱、长春碱和长春地辛的治疗效果。所有患者对含阿霉素的化疗均耐药。长春新碱通过持续输注（CI）以0.4mg/m²/1/天给药，长春碱通过CI以1.7mg/M²/1/天给药，长春地辛通过CI或在5天内间歇性推注（IB）以1.2mg/M²/1/天给药。长春新碱的疗程每2周进行一次，长春碱和长春地辛的疗程每3周进行一次。99例患者可评估疗效。接受长春新碱治疗的15例患者无客观缓解。在接受长春碱治疗的23例患者中，有2例完全缓解（9%）和5例部分缓解（22%）。在接受CI长春地辛治疗的31例患者中，有6例部分缓解（19%）。在接受IB长春地辛治疗的30例患者中，有5例部分缓解（17%）。长春碱的疾病控制中位持续时间为13周（范围8 - 140 +），CI长春地辛为18周（范围8 - 34），IB长春地辛为20周（范围12 - 47）。这些数据表明，长春碱（CI）和长春地辛（CI或IB）对难治性转移性乳腺癌患者具有显著的抗肿瘤活性，而长春新碱对类似患者没有抗肿瘤活性。
